Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.00 EUR
86.13 M EUR
280.63 M EUR
24.70 M
About Krystal Biotech, Inc.
Sector
Industry
CEO
Krish S. Krishnan
Website
Headquarters
Pittsburgh
Founded
2016
FIGI
BBG01TNXP544
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
KRYS, RSI Indicator left the overbought zone on January 07, 2021This is a signal that KRYS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked back and found 25 similar cases where KRYS's RSI Indicator left the overbought zone, and in 20 of them led to a successfu
Krystal Biotech - good entryThese are my thoughts on KRYS. They are meant to give you an idea, not trading advice.
This chart comes together like lego. Just don't step on it. Target around 80$. Could take a few months.
Dips below 40$ are my buying opportunities. Not saying it can't go lower.
Please be careful, as the mark
Extended Parabola #VolatilitywatchKRYS has hit FIB golden ratio resistance and peaked out on 5th wave. Looking for pullback to low $40's then we'll find out if it wants to fill the gap.
Please like/ comment so I can continue looking for awesome trades. Thank you in advance.
Message me if your interested in learning more on patt
Krystal Biotech Announces Positive Results from Phase 2 ClinicalKRYS: Krystal Biotech, Inc.
2019-06-24 08:00:00
Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial (“GEM-2 study”) of KB103 and Receives Regenerative Medicine Advanced Therapy (“RMAT”) Designation from FDA for KB103 - GlobeNewswire
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Related stocks
Frequently Asked Questions
The current price of 1KRYS is 147.05 EUR — it has decreased by −1.44% in the past 24 hours. Watch KRYSTAL BIOTECH INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange KRYSTAL BIOTECH INC stocks are traded under the ticker 1KRYS.
1KRYS stock has fallen by −0.068% compared to the previous week, the month change is a −0.068% fall, over the last year KRYSTAL BIOTECH INC has showed a −0.068% decrease.
We've gathered analysts' opinions on KRYSTAL BIOTECH INC future price: according to them, 1KRYS price has a max estimate of 215.59 EUR and a min estimate of 171.59 EUR. Watch 1KRYS chart and read a more detailed KRYSTAL BIOTECH INC stock forecast: see what analysts think of KRYSTAL BIOTECH INC and suggest that you do with its stocks.
1KRYS reached its all-time high on Apr 30, 2025 with the price of 149.20 EUR, and its all-time low was 146.10 EUR and was reached on Apr 25, 2025. View more price dynamics on 1KRYS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1KRYS stock is 1.46% volatile and has beta coefficient of 0.79. Track KRYSTAL BIOTECH INC stock price on the chart and check out the list of the most volatile stocks — is KRYSTAL BIOTECH INC there?
Yes, you can track KRYSTAL BIOTECH INC financials in yearly and quarterly reports right on TradingView.
KRYSTAL BIOTECH INC is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
1KRYS earnings for the last quarter are 1.47 EUR per share, whereas the estimation was 1.14 EUR resulting in a 28.36% surprise. The estimated earnings for the next quarter are 1.32 EUR per share. See more details about KRYSTAL BIOTECH INC earnings.
KRYSTAL BIOTECH INC revenue for the last quarter amounts to 88.04 M EUR, despite the estimated figure of 87.56 M EUR. In the next quarter, revenue is expected to reach 88.93 M EUR.
1KRYS net income for the last quarter is 43.93 M EUR, while the quarter before that showed 24.41 M EUR of net income which accounts for 79.96% change. Track more KRYSTAL BIOTECH INC financial stats to get the full picture.
No, 1KRYS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 4, 2025, the company has 275 employees. See our rating of the largest employees — is KRYSTAL BIOTECH INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KRYSTAL BIOTECH INC EBITDA is 106.13 M EUR, and current EBITDA margin is 37.84%. See more stats in KRYSTAL BIOTECH INC financial statements.
Like other stocks, 1KRYS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KRYSTAL BIOTECH INC stock right from TradingView charts — choose your broker and connect to your account.